Red cells with paroxysmal nocturnal hemoglobinuria-phenotype in patients with acute leukemia

Meletis, J; Terpos, E; Samarkos, M; Meletis, C; Apostolidou, E; Komninaka, V; Anargyrou, K; Korovesis, K; Mavrogianni, D; Variami, E; Viniou, N; Konstantopoulos, K

dc.contributor.author	Meletis, J	en
dc.contributor.author	Terpos, E	en
dc.contributor.author	Samarkos, M	en
dc.contributor.author	Meletis, C	en
dc.contributor.author	Apostolidou, E	en
dc.contributor.author	Komninaka, V	en
dc.contributor.author	Anargyrou, K	en
dc.contributor.author	Korovesis, K	en
dc.contributor.author	Mavrogianni, D	en
dc.contributor.author	Variami, E	en
dc.contributor.author	Viniou, N	en
dc.contributor.author	Konstantopoulos, K	en
dc.date.accessioned	2014-03-01T01:51:58Z
dc.date.available	2014-03-01T01:51:58Z
dc.date.issued	2002	en
dc.identifier.issn	10245332	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/26517
dc.relation.uri	http://www.scopus.com/inward/record.url?eid=2-s2.0-0036290541&partnerID=40&md5=ecd851222fb1a63e7ce20d975761c58f	en
dc.subject	Acute lymphoblastic leukemia (ALL)	en
dc.subject	Acute non-lymphoblastic leukemia (ANLL)	en
dc.subject	Decay-accelerating factor (DAF	en
dc.subject	CD55)	en
dc.subject	Membrane inhibitor of reactivelysis (MIRL	en
dc.subject	CD59)	en
dc.subject	Paroxysmal nocturnal hemoglobinuria (PNH)	en
dc.subject.other	decay accelerating factor	en
dc.subject.other	antineoplastic agent	en
dc.subject.other	CD59 antigen	en
dc.subject.other	glycosylphosphatidylinositol	en
dc.subject.other	regulator protein	en
dc.subject.other	sucrose	en
dc.subject.other	acute disease	en
dc.subject.other	adolescent	en
dc.subject.other	adult	en
dc.subject.other	aged	en
dc.subject.other	article	en
dc.subject.other	blood	en
dc.subject.other	diagnostic procedure	en
dc.subject.other	disease course	en
dc.subject.other	erythrocyte	en
dc.subject.other	female	en
dc.subject.other	human	en
dc.subject.other	immunology	en
dc.subject.other	incidence	en
dc.subject.other	leukemia	en
dc.subject.other	male	en
dc.subject.other	middle aged	en
dc.subject.other	paroxysmal nocturnal hemoglobinuria	en
dc.subject.other	pathology	en
dc.subject.other	phenotype	en
dc.subject.other	acute lymphoblastic leukemia	en
dc.subject.other	acute nonlymphocytic leukemia	en
dc.subject.other	antigen expression	en
dc.subject.other	bone marrow	en
dc.subject.other	cancer classification	en
dc.subject.other	cell infiltration	en
dc.subject.other	cell membrane	en
dc.subject.other	cell population	en
dc.subject.other	controlled study	en
dc.subject.other	correlation analysis	en
dc.subject.other	hematologic disease	en
dc.subject.other	human cell	en
dc.subject.other	karyotype	en
dc.subject.other	major clinical study	en
dc.subject.other	medical literature	en
dc.subject.other	medical record	en
dc.subject.other	patient information	en
dc.subject.other	priority journal	en
dc.subject.other	treatment outcome	en
dc.subject.other	Acute Disease	en
dc.subject.other	Adolescent	en
dc.subject.other	Adult	en
dc.subject.other	Aged	en
dc.subject.other	Aged, 80 and over	en
dc.subject.other	Antigens, CD55	en
dc.subject.other	Disease Progression	en
dc.subject.other	Erythrocytes	en
dc.subject.other	Female	en
dc.subject.other	Hemoglobinuria, Paroxysmal	en
dc.subject.other	Humans	en
dc.subject.other	Incidence	en
dc.subject.other	Leukemia	en
dc.subject.other	Male	en
dc.subject.other	Middle Aged	en
dc.subject.other	Molecular Diagnostic Techniques	en
dc.subject.other	Phenotype	en
dc.title	Red cells with paroxysmal nocturnal hemoglobinuria-phenotype in patients with acute leukemia	en
heal.type	journalArticle	en
heal.publicationDate	2002	en
heal.abstract	CD55 and CD59 are complement regulatory proteins that are linked to the cell membrane via a glycosyl-phosphatidylinositol anchor. They are reduced mainly in paroxysmal nocturnal hemoglobinuria (PNH) and in other hematological disorders. However, there are very few reports in the literature concerning their expression in patients with acute leukemias (AL). We studied the CD55 and CD59 expression in 88 newly diagnosed patients with AL [65 with acute non-lymphoblastic leukemia (ANLL) and 23 with acute lymphoblastic leukemia (ALL)] using the sephacryl gel test, the Ham and sucrose lysis tests and we compared the results with patients' clinical data and disease course. Eight patients with PNH were also studied as controls. Red cell populations deficient in both CD55 and CD59 were detected in 23% of ANLL patients (especially of M0, M2 and M6 FAB subtypes), 13% of ALL and in all PNH patients. CD55-deficient erythrocytes were found in 6 ANLL patients while the expression of CD59 was decreased in only 3 patients with ANLL. No ALL patient had an isolated deficiency of these antigens. There was no correlation between the existence of CD55 and/or CD59 deficiency and the percentage of bone marrow infiltration, karyotype or response to treatment. However no patient with M3, M5, M7 subtype of ANLL and mature B- or T-cell ALL showed a reduced expression of both antigens. The deficient populations showed no alteration after chemotherapy treatment or during disease course. This study provides evidence about the lower expression of CD55 and CD59 in some AL patients and the correlation with their clinical data. The possible mechanisms and the significance of this phenotype are discussed.	en
heal.journalName	Hematology	en
dc.identifier.volume	7	en
dc.identifier.issue	2	en
dc.identifier.spage	69	en
dc.identifier.epage	74	en